FountainRx holds four accreditations – two by the Utilization Review Accreditation Commission (URAC) in specialty pharmacy and mail order, and two by the Accreditation Commission for Health Care (ACHC) in specialty pharmacy and compounding. Through collaboration and commitment, FountainRx delivers comprehensive specialty pharmacy services to ensure patients’ treatment success. The company takes a patient-first approach, starting with filling prescriptions to connecting patients to financial assistance programs to providing education and resources.
“Our national footprint allows us to expand our partnerships, giving patients access to a wide array of specialized medications and services,” said Ryan Hollingsworth, PharmD, partner and chief operating officer, FountainRx. “We ensure patients have a seamless experience from the start of treatment and throughout the entire process.”
In 2024, FountainRx expanded its technology and services through strategic partnerships with ScriptMed, Inovalon’s pharmacy management software, and Pleio, Inc. to provide a concierge-level experience to patients. These partnerships will help the company to provide a superior experience as well as personalized, cost-effective care for patients as it continues to grow.
About FountainRx Specialty Pharmacy
FountainRx Specialty Pharmacy is a national, independently owned provider of specialty pharmacy and infusion services for those living with complex and persistent health conditions. The FountainRx team is dedicated to providing advanced medications, therapies, expert knowledge and support for patients. With a focus on innovation and collaboration, FountainRx strives to effectively improve health outcomes and ensure a better patient experience. Founded and headquartered in Tennessee, FountainRx is licensed in all 50 states and is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Learn more at www.fountainrx.com.
In this webinar, Fedra Molaie-Holagh, Vice President of Regulatory Affairs, will discuss key considerations across the core drug development disciplines for developing a comprehensive NDA strategy and explore opportunities for streamlining the path from EoP2 to NDA submission.
Register for this webinar today to understand how new therapies can be developed by streamlining the path from EoP2 to NDA submission.
Join Fedra Molaie-Holagh, Vice President, Regulatory Affairs, Premier Consulting, for the live webinar on Tuesday, September 24, 2024, at 11am EDT (4pm BST/UK).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Whether physicians are driven to advance medical knowledge, discover new treatment options, or build upon their professional development—community-based research can bring various benefits, such as improving upon the current standard of care, uncovering new treatment paths, or simply contributing to the greater good of medicine. For patients, they can choose what option works for their care with the guidance of their trusted physician.
In this webinar, attendees will hear directly from physicians who have partnered with Circuit Clinical’s Site Partnership Network about their experience in conducting clinical research within their respective health systems and practices. Each speaker will bring valuable insights from across their medical career journey, whether they have been conducting studies for years, are just beginning to pursue research, or have been leading research teams to achieve success.
Register for this webinar today to gain access to the three-part series on the symbiotic relationship between sponsors, patients, physicians, and community-based research sites—all of who are paving the way for a more inclusive and impactful future in medical research.
Join Irfan Khan (Moderator), MD, CEO, Circuit Clinical; Daniel Marangoni, PhD, Head of Oncology Site Operations, Circuit Clinical; Karen Pypniowski, Vice President Site Operations, Circuit Clinical; Rita Vinod Knause, MD, Chief Medical Officer, Principal Investigator, North Hudson Community Action Corporation; Dr. Priya Rimal, Medical Director of Adult and Internal Medicine, Endocrinologist/Internist, Principal Investigator, North Hudson Community Action Corporation; and Peter Ricketti, D.O., Physician and Co-Owner, Mercer Allergy & Pulmonary Associates, for the live webinar on Tuesday, September 24, 2024, at 11am EDT (4pm BST/UK).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, has announced its partnership with COTA, an organization that brings clarity to cancer care with a precise, patient-first approach based on real-world data (RWD).
BOSTON, Sept. 9, 2024 /PRNewswire-PRWeb/ — Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, has announced its partnership with COTA, an organization that brings clarity to cancer care with a precise, patient-first approach based on real-world data (RWD). Through this partnership, COTA joins Panalgo’s Partner Network and makes available their hematologic oncology data via Panalgo’s Instant Health Data Analytics (IHD) platform.
COTA has the highest quality and most complete oncology RWD from electronic health records, (EHRs). COTA’s ready-for-analysis data is sourced from a 50/50 split of academic and community care settings across the U.S. The data contain complete and concise longitudinal patient journeys that support regulatory submissions and help to answer research questions involving treatment patterns, real-world outcomes, care comparisons, and more.
The collaboration will initially focus on COTA’s hematologic oncology data, with plans to add solid tumor data in the future. The partnership also includes research collaborations and AI/technology co-development opportunities.
“We are delighted to join Panalgo’s data network as their first oncology partner specializing in hematologic cancers,” said COTA’s chief commercial officer, Sandy Leonard. “COTA’s longitudinal, high-quality oncology data enables researchers to generate meaningful insights that support decision making across life science organizations. By leveraging Panalgo’s analytics platform, we can accelerate the speed and eliminate some of the operational barriers to generating these insights.”
Panalgo’s IHD Analytics is the industry leading self-service, enterprise RWE analytical platform enabling rapid analytics and insights. With no complex programming required, it’s 85% faster than traditional custom programming, with a unique, healthcare-specific data model and extensive library of customizable algorithms, plus integrated machine learning and automated documentation. IHD gives you answers to questions in real time by conducting risk evaluations, evaluating access to treatment, exploring the impact of regulatory action, and examining emergent safety issues. It lets you generate evidence for the effectiveness, safety, and value of your treatments more fully with speed and at scale.
“COTA’s addition to Panalgo’s Partner Network offers life science organizations an innovative approach to access their specialized hematologic oncology RWD quickly through Panalgo’s IHD platform” said Erik Maul, Senior Director of Partnerships at Panalgo. ” We are excited to collaborate with COTA and continue making significant steps forward in breaking away from the traditional process and constraints of leveraging real-world data. By streamlining access to insights, we can accelerate real-world evidence generation and improve healthcare outcomes.”
About COTA, Inc.
Founded by oncologists, COTA is committed to creating a precise, patient-first approach to cancer care using real-world data. The company leverages technology-supported data abstraction methods to make sense of complex, fragmented patient data from the real world. Offering the highest quality oncology real-world data from leading academic and community-based cancer centers and an advanced analytics platform, COTA partners with leading life sciences companies, providers, and payers to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to fast-track improvements in cancer care and treatment with comprehensive and diverse real-world data and analytics, visit cotahealthcare.com.
About Panalgo
Panalgo, a Norstella company, is your partner on the healthcare data analytics journey. Our Instant Health Data (IHD) platform eliminates complex programming, making data analysis faster and decision-making more impactful. Through partnerships across the industry, we streamline access to real-world data, offering a complete solution from data to insights. Whether it’s industry-leading software, access to data, expert analytic services, or any combination of the three, we’re here to support you at any stage of your analytics journey. For more information visit Panalgo.com and follow us on LinkedIn.
For more information or to leverage COTA data in Panalgo’s IHD platform, contact us today.
Beachside Fun at the 2024 Dental Sleep Medicine Symposium, November 8-9 in Ft. Lauderdale, FL! Featuring 13 experts, hourly topics on Dental Sleep Medicine and TMD, plus optional breakouts on Medical Billing and Sleep Coordinator Roles.
FT. LAUDERDALE, Fla., Sept. 9, 2024 /PRNewswire-PRWeb/ — Nierman Practice Management is pleased to announce the 2024 Dental Sleep Medicine Symposium, which is being held on November 8-9, 2024, at the Fort Lauderdale Marina Hotel in Ft. Lauderdale, Florida.
This symposium offers an important opportunity for dentists and their teams to expand their expertise in treating sleep apnea and enhancing their practice.
The event will feature the latest developments in dental sleep medicine, along with clinical sessions, medical billing training, and practical business insights.
Attendees will benefit from 1.5 days of comprehensive sessions and networking opportunities with respected educators, mentors, and industry professionals.
“Our goal is to bring the dental sleep medicine community together to learn, network, and grow. We encourage dentists to bring their teams to gain actionable knowledge that will ignite new possibilities for their dental sleep medicine practice,” said Jon Nierman, President of Nierman Practice Management.
The symposium’s agenda includes topics such as:
Sleep Apnea & TMD
Treating Pediatric Airway Patients
Myofunctional Therapy
Medical Billing for Dental Sleep Medicine
Practice Growth through Referrals
In addition to a long list of educational sessions, attendees will have the chance to participate in an evening networking reception that will provide a valuable forum for dental professionals to connect, share insights, and explore the latest innovations in dental sleep devices, home sleep testing, practice management solutions, and patient care services.
The symposium will feature a distinguished roster of speakers, including: Dr. Michael Gelb, Dr. Mayoor Patel, Dr. Ryan Robinson, Dr. Steve Lamberg, Dr. Anjoo Ely, Dr. Alan Blanton, Karese Laguerre, CRDH, MAS, Dr. Andrew Cohen, Dr. Ken Mogell, Dr. Joanna Green and Michael Cowen.
Rose Nierman, CEO at Nierman Practice management will also be holding an exclusive medicinal billing course showcasing her expertise on all the latest codes, helping you to get the most money for your practice.
Attendees will earn 12 CE credits accredited by AGD PACE.
Tickets are available on the Nierman Practice Management website now! (Click here)
“In recent years, the suppliers of EO Indicator Tape exited the market when components required to make the tape became scarce during the pandemic. In response to this void in the marketplace, Propper dedicated time, effort and resources to meet the challenge of filling the gap and we are very happy to announce that Propper has received FDA clearance for EO Chex. As of today, our product is the only FDA cleared EO Tape available for sale in the United States” – Joe Looney, President & CEO – Medical
According to the U.S. Food and Drug Administration (FDA), roughly 50 percent of all medical devices in the country are sterilized using ethylene oxide. For many of these devices, EO is the only method to effectively sterilize them without damage from the sterilization process. Use EO Chex Tape with Gas-Chex® Internal Indicators and BI-OK® EO Biological Indicator to verify your ethylene oxide cycle meets the criteria for a satisfactory sterilization process.
About EO Chex
EO Chex™ Indicator Tape is a pressure-sensitive tape with Ethylene Oxide (EO) process indicator suitable for use in securing sterilization packaging materials EO processing.
EO Chex Tape conforms to the requirements of ISO 11140-1:2014, Type 1 with the following stated values:
37°C, 600mg/L EO, 25 min, 60% RH
54°C, 600mg/L EO, 20 min, 60% RH
The indicator is suitable for the sterilization cycles found in Table 1.
EO Chex™ Indicator Tape is available for sale from Propper Manufacturing Company or through all major distributors. Contact Propper Manufacturing Company or your distributor representative for contracted pricing.
About: Propper Manufacturing Company is a trusted partner to healthcare professionals worldwide by providing reliable and innovative products, services, and educational resources that promote safety and help reduce healthcare-acquired infections. Propper is committed to using the latest technology and research to continuously improve its products and services while prioritizing exceptional customer service and support.
During the HBCU NY Classic, members of Alpha Phi Alpha Fraternity, Inc., Alpha Kappa Alpha Sorority, Inc., Kappa Alpha Psi Fraternity, Inc., Omega Psi Phi Fraternity, Inc., Delta Sigma Theta Sorority, Inc., Zeta Phi Beta Sorority, Inc., Phi Beta Sigma Fraternity, Inc., Sigma Gamma Rho Sorority, Inc., and Iota Phi Theta Fraternity, Inc., will participate in the World’s Largest Black Greek Stroll Line – a historic event in two ways:
First-Ever in an NFL Stadium: Witness the electrifying energy of the Divine Nine stroll unfold within the iconic MetLife Stadium.
The Divine Nine Unity Stroll will symbolize that the D9 stands in unity to Get Out The Vote. This event kicks off one of the most powerful and impactful voter mobilization campaigns of this historic election season. #d9strongertogether
Show Your D9 Pride and Support Education:
Not only will this event be historic, but the Divine 9 organization with the largest number of strollers will be awarded a $10,000 donation to its Educational Foundation.
Don’t Miss Out!
This is a once-in-a-lifetime opportunity to showcase the Divine Nine spirit, celebrate HBCUs, and see Sean Paul perform on a national platform.
Here’s what makes the HBCU New York Classic even more special:
A Five-Day Festivity: The HBCU New York Classic spans a five-day festivity that showcases the culture and community activities of Historically Black Colleges and Universities (HBCUs), culminating in a football game between two HBCU teams at MetLife Stadium. This yearly event pits teams from the Mid-Eastern Athletic Conference (MEAC) against those from the Southern Intercollegiate Athletic Conference (SIAC) and is organized by Sports Eleven05. The Classic is televised live on CNBC.
Get Out the Vote Campaign: In this election season, the NY HBCU Classic will also serve as a platform to engage the 35,000 fans and tailgaters in one of the largest Get Out The Vote events.
The pre-game will feature the “Divine 9 Classic Stroll Line”. A show of unity and symbolic of “Strolling to the Polls” this will be the very first of its kind to occur in an NFL Stadium. Also, the HBCU community, members of the D9 and other community-based organizations will be on-site for voter registration, to encourage voter mobilization, and solicit election volunteers.
HBCU Reception: The HBCU After Party: begins immediately following the game. 2024 HBCU Cocktail Reception Featuring Music by “The Legendary Chris Washington” Beginning at 7:00, the festivities will be held at the Meadowlands Hilton. Two Meadowlands Plaza, East Rutherford, NJ 07073 Tickets are $125.00 and can be purchased via this linkhttps://bit.ly/2024D9Stroll
Quote:
“MetLife Stadium is honored to host the third annual HBCU New York Classic,” said Ron VanDeVeen, President and CEO of MetLife Stadium. “HBCU New York Classic is an outstanding event and we look forward to welcoming Morehouse College, Howard University and thousands of HBCU alumni and fans to our stadium this September.”
“We are thrilled to host the HBCUNY Classic once again at MetLife Stadium,” said Albert Williams, President & CEO of Sports Eleven05 LLC, the producers of the Classic. “This game not only celebrates the rich athletic traditions of Morehouse and Howard University but also underscores the importance of HBCUs in higher education. It’s an opportunity for alumni, students, and fans to come together in the spirit of camaraderie and competition.”
Visitwww.hbcunyclassic.com for more information and secure your tickets for the HBCU New York Classic!
Join us on September 14th and be a part of this unforgettable event!
About The HBCU New York Classic
The HBCU New York Classic spans a five-day festivity that showcases the culture and community activities of Historically Black Colleges and Universities (HBCUs), culminating in a football game between two HBCU teams at MetLife Stadium. This yearly event pits teams from the Mid-Eastern Athletic Conference (MEAC) against those from the Southern Intercollegiate Athletic Conference (SIAC) and is organized by Sports Eleven05. The classic is televised live on CNBC. For further details and to stay updated on ticket information, please visit www.hbcunyclassic.com.
About MetLife Stadium
MetLife Stadium, located in East Rutherford, NJ, is the home of the New York Jets and New York Football Giants. It is one of the largest stadiums in the NFL with a capacity of 82,500. MetLife Stadium hosts the world’s biggest events on the world’s biggest stage and will serve as host stadium for the FIFA World Cup 2026™ Final. MetLife Stadium has hosted over 550 major events and 3,000 special events. Event highlights include the first outdoor, cold-weather Super Bowl XLVIII, WrestleMania 29 and 35, the Copa America Centenario Final, the 2021 Army-Navy Game, and many concerts, college football games, and international soccer matches.
The new fertility center will be led by Boston IVF reproductive endocrinologists Drs. Emily Seidler and Riwa Sabbagh – who will begin treating patients in Fall 2024. Additionally, Dr. Jill Attaman will join the Concord fertility team in early 2025. Each physician specializes in all aspects of fertility treatment and care.
Sharon Edwards, RN, Boston IVF Chief Operating Officer expressed her enthusiasm for the new center, stating, “Our new Concord center stands as a testament to our commitment to advancing fertility care, while also ensuring the Concord community has access to the exceptional access to state-of-the-art treatments and groundbreaking innovations in reproductive medicine which they deserve.”
#1 Private Group for Top Doctors in Reproductive Medicine in Massachusetts
#1 Private Group for Top Doctors in Women’s Health in Massachusetts
#1 Private Group for Top Doctors in Reproductive Medicine in the Boston Metro Area
#1 Private Group for Top Doctors in Women’s Health in the Boston Metro Area
Massachusetts has the higher percentage (7%) of babies born as a result of fertility treatment in the US. Boston IVF is a pioneer in the field and having fertility centers close to home and work makes the burden of treatment easier for patients, resulting in greater access to care.
For more information about the new Concord location, its care team, or to schedule an appointment, please visit www.bostonivf.com.
Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include 40 reproductive endocrinologists across nearly 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts. In 2024, Boston IVF joined the global IVI RMA Network, contributing to the network’s management of more than 20+ labs and 60 satellites across North America.
Watch to discover how technology and innovation are beckoning change.
JUPITER, Fla., Sept. 9, 2024 /PRNewswire-PRWeb/ — Tune in to Bloomberg on Saturday, September 14, 2024, to watch a new episode of Advancements, hosted by Ted Danson.
Coming up, learn about the importance of preserving biodiversity as Advancements explores how S.E.A. Aquarium, by Resort World Sentosa (RWS), contributes to research and to the preservation of marine life. See how aquariums act as a platform for education, while discovering how S.E.A. Aquarium provides opportunities for people to engage with and learn about biodiversity, as well as how it promotes education, the importance of marine conservation, and biodiversity as a way to better the state of our oceans.
Next, learn about the need to provide at-risk populations with access to available treatments today. Hearing from experts, viewers will learn how Esperion Therapeutics (Esperion) works to discover, develop, and commercialize innovative medicines to help improve outcomes for patients who are at risk for or have cardiovascular and cardiometabolic diseases, while breaking through the barriers that prevent patients from reaching their heart health goals.
With a look at the demand for mental healthcare in the U.S., audiences will learn about Hero Journey Club (HJC), which brings high-level mental healthcare to those who might not otherwise have had access to traditional care. The show will share how group settings allow HJC mental health practitioners the ability to work with more participants than a one-on-one setting, helping to lower costs and enable more people to get the care they need.
Finally, discover how artificial intelligence is being used to improve brain health diagnosis as the show shares how ViewMind analyzes eye movement patterns to provide a high precision measurement of brain health. Spectators will see how the solution for precision diagnostics and measurement of neurocognitive health is being used to help predict Alzheimer’s before the sign of symptoms appear.
“This episode is full of innovative and engaging content that is sure to enlighten and entertain audiences,” said Chad Densen, production manager for DMG Productions and the Advancements series. “We are excited to share this information with viewers.”
About Advancements and DMG Productions: Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative environmental and sustainable solutions responsible for shaping, molding, and transforming the world.
DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks. Focused on the major innovations and advancements responsible for global progress today, its team of award-winning writers, directors, and producers go on location to discover and share how technology and innovation continue to drive the world forward.
